Shots:
- JCR Pharmaceuticals & Alexion have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines
- As per the deal, Alexion may use licensed capsids from the JUST-AAV platform in up to 5 genomic medicine programs in exchange for an undisclosed upfront payment, ~$225M in R&D milestones, ~$600M in sales milestones (milestones totaling to ~$825M if all targets are exercised), plus tiered royalties on net sales
- JUST-AAV platform utilizes modified AAV vectors with miniaturized antibodies on the capsid surface to help target selected tissues, organs, or the BBB, while further capsid modifications reduce side effects & improve safety
Ref: Businesswire | Image: Alexion & JCR Pharmaceuticals | Press Release
Related News:- JCR Pharmaceuticals and Modalis Progress into the Next Phase of Joint Research Agreement to Develop Gene Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
